ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
The ImmunoGen deal, which is expected to close in the middle of 2024, is also estimated to be accretive to AbbVie’s diluted earnings per share beginning in 2027.
1Q 2023 ZYNLONTA®1 net sales increased 15% and operating expenses decreased 19% year-over-year2; FY 2023 guidance reaffirmed for ZYNLONTA double-digit net sales growth and reduction in operating. | May 9, 2023
1Q 2023 ZYNLONTA®1 net sales increased 15% and operating expenses decreased 19% year-over-year2; FY 2023 guidance reaffirmed for ZYNLONTA double-digit net sales growth and reduction in operating expenses
Operator: Welcome to the ADC Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. My name is Andrew, and I ll be your operator for today s call.